Cytokinetics Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, Cytokinetics stock has a consensus rating of "Buy" and an average price target of $109.42. The average 1-year stock price forecast is 98.44% higher than the current stock price, while the lowest is $78 (+41.46%) and the highest is $146 (+164.78%).

Price Target: $109.42 (+98.44%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$78	$109.42	$107	$146
Change	+41.46%	+98.44%	+94.05%	+164.78%

Analyst Ratings

The average analyst rating for Cytokinetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26	Nov '26
Strong Buy	13	13	13	13	13	13
Buy	7	7	7	7	7	7
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	22	22	22	22	22	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $140	Buy	Reiterates	$140	+153.90%	Nov 9, 2026
Srikripa Devarakonda Truist Financial	Truist Financial	Buy Reiterates $112	Buy	Reiterates	$112	+103.12%	Nov 6, 2026
Cory Kasimov Evercore ISI	Evercore ISI	Buy Maintains $100	Buy	Maintains	$100	+81.36%	Nov 5, 2026
Leonid Timashev RBC Capital	RBC Capital	Buy Maintains $113	Buy	Maintains	$113	+104.93%	Nov 5, 2026
Unknown Analyst Leerink Partners No rating	Leerink Partners	Buy Reiterates $103 → $100	Buy	Reiterates	$103 → $100	+81.36%	Nov 5, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

164.78M

from 88.04M

87.17%

from 88.04M

Revenue Next Year

446.39M

from 164.78M

170.90%

from 164.78M

EPS This Year

-5.78

from -6.54

EPS Next Year

-4.25

from -5.78

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	70.43M	94.59M	7.53M	18.47M	88.04M	164.78M
Revenue Growth	26.15%	34.31%	-92.04%	145.34%	376.56%	87.17%
Operating Income	-186.31M	-324.20M	-496.21M	-536.25M	-612.26M	-706.55M
Net Income	-215.31M	-388.96M	-526.24M	-589.53M	-784.96M	-799.17M
EPS	-	-	-	-	-6.54	-5.78
Free Cash Flow	-	-	-	-	-534.82M	-702.87M
No. Analysts	-	-	-	-	-	17

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	223.7M
Avg	164.8M
Low	151.5M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	154.0%
Avg	87.2%
Low	72.1%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-4.64
Avg	-5.78
Low	-6.27

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-